Abstract:Background The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy for hepatocellular carcinoma (HCC), however, not all patients respond successfully to this treatment. A major challenge for HCC immunotherapy is the development of ways to screen for those patients that would benefit from this type of treatment and determine the optimal treatment plan for individual patients. Therefore, it is important to find a biomarker which allows for the stratification of HCC patients, which distinguishes responders from non-responders, thereby further improving the clinical benefits for those undergoing immunotherapy. Methods We used univariate and multivariate Cox risk proportional regression models to evaluate the relationship between non-synonymous mutations with a mutation frequency greater than 10%. We made a prognosis of an immunotherapy HCC cohort using mutation and prognosis data. An additional three HCC queues from the cbioportal webtool were used for further verification. The CIBERSORT, IPS, quanTIseq, and MCPcounter algorithms were used to evaluate the immune cells. PCA and z-score algorithm were used to calculate immune-related signature with published gene sets. Gene set enrichment analysis (GSEA) was used to compare the differences in the pathway-based enrichment scores of candidate genes between mutant and wild types. Results Univariate and multivariate Cox results showed that only CTNNB1-Mutant(CTNNB1-MUT) was associated with progression-free survival (PFS) of HCC patients in the immunotherapy cohort. After excluding the potential bias introduced by other clinical features, it was found that CTNNB1-MUT served as an independent predictor of the prognosis of HCC patients after immunotherapy (P < 0.05; HR > 1). The results of the tumor immune microenvironment (TIME) analysis showed that patients with CTNNB1-MUT had significantly reduced activated immune cells [such as T cells, B cells, M1-type macrophages, and dendritic cells (DCs)], significantly increased M2-type macrophages, a significantly decreased expression of immunostimulating molecules, low activity of the immune activation pathways (cytokine pathway, immune cell activation and recruitment) and highly active immune depletion pathways (fatty acid metabolism, cholesterol metabolism, and Wnt pathway). Conclusions In this study, we found CTNNB1-MUT to be a potential biomarker for HCC immunotherapy patients, because it identified those patients are less likely to benefit from ICIs.

Comparison of Immune Profiles Between Hepatocellular Carcinoma Subtypes

Heterogeneous Responses in Hepatocellular Carcinoma: the Achilles Heel of Immune Checkpoint Inhibitors.

Immune Classifier-Based Signatures Provide Good Prognostic Stratification and Predict the Clinical Benefits of Immune-Based Therapies for Hepatocellular Carcinoma

Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis

The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma

Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma

Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients

Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma

Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma

Identification of immune subtypes and prognosis of hepatocellular carcinoma based on immune checkpoint gene expression profile.

Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis

Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma

CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma

The Heterogeneity of Genomic Biomarkers for Immune Checkpoint Inhibitor in Therapy-Naïve Primary Hepatocellular Carcinoma and Their Metachronous Metastases.